Mónica Roldán

Mónica Roldán

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ALArístides López-Márquez
Arístides López-Márquez
MMMatias Morin
Matias Morin
SFSergio Fernández-Peñalver
Sergio Fernández-Peñalver
CBCarmen Badosa
Carmen Badosa
AHAlejandro Hernández-Delgado
Alejandro Hernández-Delgado
CJCecilia Jimenez-Mallebrera
Cecilia Jimenez-Mallebrera
Collagen VI-related disorders are the second most common congenital muscular dystrophies for which no treatments are presently available. They are mostly caused by dominant-negative pathogenic variants in the genes encoding α chains of collagen VI, a heteromeric network forming collagen; for example, the c.877G>A; p.Gly293Arg COL6A1 variant, which alters the proper association of the tetramers to form microfibrils. We tested the potential of CRISPR/Cas9-based genome editing to silence or correct (using a donor template) a mutant allele in the dermal fibroblasts of four individuals bearing the c.877G>A pathogenic variant. Evaluation of gene-edited cells by next-generation sequencing revealed that correction of the mutant allele by homologous-directed repair occurred at a frequency lower than 1%. However, the presence of frameshift variants and others that provoked the silencing of the mutant allele were found in >40% of reads, with no effects on the wild-type allele. This was confirmed by droplet digital PCR with allele-specific probes, which revealed a reduction in the expression of the mutant allele. Finally, immunofluorescence analyses revealed a recovery in the collagen VI extracellular matrix. In summary, we demonstrate that CRISPR/Cas9 gene-edition can specifically reverse the pathogenic effects of a dominant negative variant in COL6A1.

Verified
Journal Article
Open access
PDF file
Enrico CastroflorioEnrico Castroflorio
Enrico Castroflorio
Ana Joaquina Perez-BernaAna Joaquina Perez-Berna
Ana Joaquina Perez-Berna
ALArístides López-Márquez
Arístides López-Márquez
CBCarmen Badosa
Carmen Badosa
PLPablo Loza-Alvarez
Pablo Loza-Alvarez
CJCecilia Jimenez-Mallebrera
Cecilia Jimenez-Mallebrera
Collagen VI-related disorders (COL6-RD) represent a severe form of congenital disease for which there is no treatment. Dominant-negative pathogenic variants in the genes encoding α chains of collagen VI are the main cause of COL6-RD. Here we report that patient-derived fibroblasts carrying a common single nucleotide variant mutation are unable to build the extracellular collagen VI network. This correlates with the intracellular accumulation of endosomes and lysosomes triggered by the increased phosphorylation of the collagen VI receptor CMG2. Notably, using a CRISPR-Cas9 gene-editing tool to silence the dominant-negative mutation in patients’ cells, we rescued the normal extracellular collagen VI network, CMG2 phosphorylation levels, and the accumulation of endosomes and lysosomes. Our findings reveal an unanticipated role of CMG2 in regulating endosomal and lysosomal homeostasis and suggest that mutated collagen VI dysregulates the intracellular environment in fibroblasts in collagen VI-related muscular dystrophy.

29 July 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
EGElena Godoy-Molina
Elena Godoy-Molina
NSNatalia L. Serrano
Natalia L. Serrano
AJAquilina Jiménez-González
Aquilina Jiménez-González
MVMiquel Villaronga
Miquel Villaronga
RPRosa M. Marqués Pérez-Bryan
Rosa M. Marqués Pérez-Bryan
FPFrancesc Palau
Francesc Palau

28 March 2025 in Cancer Discovery
Verified
Journal Article
Closed access
SCSandra D. Castillo
Sandra D. Castillo
XPXabier Perosanz
Xabier Perosanz
ARAndrew K. Ressler
Andrew K. Ressler
MIMarta Ivars
Marta Ivars
JRJairo Rodríguez
Jairo Rodríguez
MGMariona Graupera
Mariona Graupera
PTEN hamartoma tumor syndrome (PHTS) is a rare tumor risk disorder caused by germline loss-of-function mutations in PTEN. Half of these patients develop vascular malformations, a hamartoma characterized by overgrowth of vessels. In this study, we harness biopsies and patient-derived endothelial cells (EC) to study the genetic etiology of PHTS-related vascular malformations. We discover that these lesions are generated by somatic loss of the PTEN wild-type allele through copy-neutral loss of heterozygosity, leading to somatic uniparental disomy of the PTEN-mutated allele in ECs. We established a mouse model of PHTS-related vascular malformations and identified that the mTOR inhibitor rapamycin and AKT inhibitor capivasertib block vascular lesion growth. As proof-of-concept for clinical activity, off-label treatment with rapamycin of two patients with PHTS reduced vascular overgrowth and abrogated lesion-associated pain. Overall, our results uncover the genetic cause of vascular malformations in patients with PHTS and open new avenues for therapeutic intervention. Significance: Somatic loss of PTEN in ECs causes vascular malformations in patients with the tumor risk syndrome PHTS. These lesions respond to PI3K signaling inhibition. See related commentary by Del Prior and Toker, p. 1306

Verified
Journal Article
Open access
PDF file
CJCristina Jou
Cristina Jou
ANAndres Nascimento
Andres Nascimento
ABAnna Codina Bergada
Anna Codina Bergada
JVJulio Montoya Villarroya
Julio Montoya Villarroya
EGEster Lopez Gallardo
Ester Lopez Gallardo
RARafael Artuch
Rafael Artuch
Thymidine kinase (TK2) deficiency causes mitochondrial DNA depletion syndrome. We aimed to report the clinical, biochemical, genetic, histopathological, and ultrastructural features of a cohort of paediatric patients with TK2 deficiency. Mitochondrial DNA was isolated from muscle biopsies to assess depletions and deletions. The TK2 genes were sequenced using Sanger sequencing from genomic DNA. All muscle biopsies presented ragged red fibres (RRFs), and the prevalence was greater in younger ages, along with an increase in succinate dehydrogenase (SDH) activity and cytochrome c oxidase (COX)-negative fibres. An endomysial inflammatory infiltrate was observed in younger patients and was accompanied by an overexpression of major histocompatibility complex type I (MHC I). The immunofluorescence study for complex I and IV showed a greater number of fibres than those that were visualized by COX staining. In the ultrastructural analysis, we found three major types of mitochondrial alterations, consisting of concentrically arranged lamellar cristae, electrodense granules, and intramitochondrial vacuoles. The pathological features in the muscle showed substantial differences in the youngest patients when compared with those that had a later onset of the disease. Additional ultrastructural features are described in the muscle biopsy, such as sarcomeric de-structuration in the youngest patients with a more severe phenotype.

Verified
Journal Article
Open access
PDF file
AVAmerica Vera-Montecinos
America Vera-Montecinos
JGJordi Galiano-Landeira
Jordi Galiano-Landeira
MRMónica Roldán
Mónica Roldán
FVFrancisco Vidal-Domènech
Francisco Vidal-Domènech
ECEnrique Claro
Enrique Claro
BRBelen Ramos
Belen Ramos
Methyltransferase-like protein 7A (METTL7A) is a member of the METTL family of methyltransferases.Little information is available regarding the cellular expression of METTL7A in the brain. METTL7A is commonly located in the endoplasmic reticulum and to a lesser extent, in the lipid droplets of some cells. Several studies have reported altered protein and RNA levels in different brain areas in schizophrenia. One of these studies found reduced protein levels of METTL7A in the cerebellar cortex in schizophrenia and stress murine models. Since there is limited information in the literature about METTL7A, we characterized its cellular and subcellular localizations in the human cerebellum using immunohistochemical analysis with laser confocal microscopy. Our study reveals a novel METTL7A localization in GFAP-positive cells, with higher expression in the end-feet of the Bergmann glia, which participate in the cerebrospinal fluid–brain parenchyma barrier. Further 3D reconstruction image analysis showed that METTL7A was expressed in the contacts between the Bergmann glia and Purkinje neurons. METTL7A was also detected in lipid droplets in some cells in the white matter. The localization of METTL7A in the human cerebellar glia limitans could suggest a putative role in maintaining the cerebellar parenchyma homeostasis and in the regulation of internal cerebellar circuits by modulating the synaptic activity of Purkinje neurons.